Spolidório, Luis Carlos [UNESP]Holzhausen, Marinella [UNESP]Palomari Spolidorio, Denise M. [UNESP]Nassar, Carlos A. [UNESP]Nassar, Patricia O. [UNESP]Muscará, Marcelo Nicolás2014-05-272014-05-272005-09-01Journal of Periodontology, v. 76, n. 9, p. 1520-1525, 2005.0022-3492http://hdl.handle.net/11449/68399Background: Cyclosporin (CsA) and tacrolimus (FK-506) are immunosuppressive drugs that specifically inhibit T-cell activation via calcineurin inhibition. Gingival overgrowth is a common side effect following the administration of CsA. The severity of gingival overgrowth seen in patients taking FK-506 is less than that observed with CsA. Little is known about the involvement of saliva in drug-induced gingival overgrowth. The purpose of this study was to investigate the salivary contents of tumor growth factor β1 (TGF-β1), epidermal growth factor (EGF), and interleukin-6 (IL-6) as well as the hystometry of gingival tissue obtained from rats treated with either FK-506 or CsA. Methods: For 30 or 60 days rats received daily subcutaneous injection doses of either CsA or FK-506 (10 mg/kg). The concentrations of TGF-β1, EGF, and IL-6 in saliva were determined by enzyme-linked immunosorbent assay, and after histological processing, the oral epithelium and connective tissue were assessed at the region of the lower first molars. Results: The levels of TGF-β1, EGF, and IL-6 in saliva were not significantly altered by any of the treatments after 30 days. After 60 days of treatment with CsA, gingival overgrowth and significant increase in salivary TGF-β1, EGF, and IL-6 concentrations were observed; no statistically significant changes were induced by FK-506. Conclusion: Within the limits of this experimental study, it can be concluded that CsA, but not FK-506, induced gingival overgrowth associated with an increase of the salivary levels of the cytokines TGF-β1, EGF, and IL-6.1520-1525engAnimal studiesCyclosporin A/adverse effectsGingival hyperplasia/etiologyGrowth factors, epidermalGrowth factors, tumor β1Interleukin-6Saliva/analysisTacrolimus/adverse effectscyclosporincytokineepidermal growth factorinterleukin 6tacrolimustransforming growth factor beta1animal experimentanimal modelanimal tissueconcentration responseconnective tissuecontrolled studyenzyme linked immunosorbent assayfibroblastgingiva overgrowthhistometrymalemolar toothmouth mucosanonhumanratsalivationAnimalsCyclosporineCytokinesEpidermal Growth FactorGingival OvergrowthImmunosuppressive AgentsMaleRatsRats, Sprague-DawleySalivaTacrolimusTransforming Growth Factor betaTransforming Growth Factor beta1Artigo10.1902/jop.2005.76.9.1520Acesso restrito2-s2.0-269444641772640929291808415